Objective: To investigate the effects of dydrogesterone (DYD), a synthetic progestin largely used in hormone therapy, on the central nervous system by studying two markers of the neuroendocrine function: the neurosteroid allopregnanolone and the opioid β-endorphin. Design: Experimental study on animal model. Setting: Academic research environment. Animal(s): 72 Wistar female rats. Intervention(s): One group of fertile and one of ovariectomized rats (receiving placebo) were used as control. After ovariectomy, the rats underwent a 2-week oral treatment of DYD (0.2, 0.6, or 1.0 mg/kg per day), alone or with estradiol valerate (E2V; 0.05 mg/kg per day). Main Outcome Measure(s): Allopregnanolone and β-endorphin, assessed in different brain areas and in circulation. Result(s): Ovariectomy decreased allopregnanolone anywhere except in the adrenal gland and reduced β-endorphin central levels; E2V reversed the effects of ovariectomy; and DYD (1 mg/kg per day) increased allopregnanolone levels in frontal lobe, hippocampus, and hypothalamus. Combined administration of DYD at 1 mg/kg per day plus E2V determined a further increase of allopregnanolone levels in frontal lobe, hippocampus, hypothalamus, and serum. Dydrogesterone did not modify the levels of β-endorphin induced by E2V. Conclusion(s): Dydrogesterone interacts with allopregnanolone levels (less with β-endorphin), and it can be considered important modulator of the neuroendocrine function. © 2008 American Society for Reproductive Medicine.
Pluchino, N., Lenzi, E., Casarosa, E., Cela, V., Begliuomini, S., Ninni, F., et al. (2007). Dydrogesterone increases allopregnanolone in selected brain areas and in serum of female rats. FERTILITY AND STERILITY, 24(5), 1384-1389 [10.1016/j.fertnstert.2007.03.077].
Dydrogesterone increases allopregnanolone in selected brain areas and in serum of female rats
LUISI, S.;
2007-01-01
Abstract
Objective: To investigate the effects of dydrogesterone (DYD), a synthetic progestin largely used in hormone therapy, on the central nervous system by studying two markers of the neuroendocrine function: the neurosteroid allopregnanolone and the opioid β-endorphin. Design: Experimental study on animal model. Setting: Academic research environment. Animal(s): 72 Wistar female rats. Intervention(s): One group of fertile and one of ovariectomized rats (receiving placebo) were used as control. After ovariectomy, the rats underwent a 2-week oral treatment of DYD (0.2, 0.6, or 1.0 mg/kg per day), alone or with estradiol valerate (E2V; 0.05 mg/kg per day). Main Outcome Measure(s): Allopregnanolone and β-endorphin, assessed in different brain areas and in circulation. Result(s): Ovariectomy decreased allopregnanolone anywhere except in the adrenal gland and reduced β-endorphin central levels; E2V reversed the effects of ovariectomy; and DYD (1 mg/kg per day) increased allopregnanolone levels in frontal lobe, hippocampus, and hypothalamus. Combined administration of DYD at 1 mg/kg per day plus E2V determined a further increase of allopregnanolone levels in frontal lobe, hippocampus, hypothalamus, and serum. Dydrogesterone did not modify the levels of β-endorphin induced by E2V. Conclusion(s): Dydrogesterone interacts with allopregnanolone levels (less with β-endorphin), and it can be considered important modulator of the neuroendocrine function. © 2008 American Society for Reproductive Medicine.File | Dimensione | Formato | |
---|---|---|---|
Dydrogesterone.pdf
non disponibili
Tipologia:
Abstract
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
265.52 kB
Formato
Adobe PDF
|
265.52 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/11922
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo